{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BeiGene, Ltd."},"Symbol":{"label":"Symbol","value":"BGNE"},"Address":{"label":"Address","value":"94 SOLARIS AVENUE,CAMANA BAY, GRAND CAYMAN, KY1-1108, Cayman Islands"},"Phone":{"label":"Phone","value":"+1 345 949-4123"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Caribbean"},"CompanyDescription":{"label":"Company Description","value":"BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world."},"CompanyUrl":{"label":"Company Url","value":"https://www.beigene.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christiane Langer","title":"Senior Vice President-Global Medical Affairs"},{"name":"Ed Fitzgerald","title":"Vice President & Head-Global Engineering"},{"name":"John V. Oyler","title":"Chairman & Chief Executive Officer"},{"name":"Kyu-Sung Lee","title":"SVP, Head-Technical Operations & Manufacturing"},{"name":"Lai Wang","title":"Global Head-Research & Development"},{"name":"Xiao Bin Wu","title":"President, Chief Operating Officer & GM-China"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}